Acurx Pharmaceuticals, Inc. approved voluntary 10% base salary reductions for key executives and cash compensation for non-employee directors effective April 1, 2026, and announced a new open-label pilot trial for ibezapolstat in up to 20 patients with multiply-recurrent C. difficile infection, with start-up later this month and first enrollment in Q4 2026.
Key takeaways
Compensation Committee approved 10% base salary reductions effective April 1, 2026: David P. Luci (President/CEO) to $495,000; Robert J. DeLuccia (Executive Chairman) to $495,000; Robert G. Shawah (CFO) to $360,000.
10% reduction to cash components of non-employee director compensation effective April 1, 2026.
New open-label pilot trial in up to 20 patients with at least two recurrences of CDI within past 12 months; trial start-up later this month, first-patient enrollment Q4 2026.
Data from pilot to inform planned active-controlled Phase 3 registration trial in rCDI.
Plans to seek FDA approval under LPAD pathway for treatment and prevention of rCDI following successful Phase 3.